source
- FDA staff raise concerns over data for Moderna’s mFlusiva flu vaccine ahead of advisory panelFDA staff have examined the evidence for Moderna's mFlusiva, an mRNA flu vaccine, and highlighted shortcomings in the data submitted to the agency. The Food and Drug Administration will convene an…
- Edgewise Therapeutics moves heart disease drug into Phase 3 after updated Phase 2 dataEdgewise Therapeutics announced on June 16, 2026 that it will advance its investigational therapy for a genetic heart disease into a registrational Phase 3 trial. The decision follows an updated a…